The utility of

To compare three fluorine-18-fluorodeoxyglucose positron emission tomography (Forty NSCLC patients underwentThe number of complete metabolic response (CMR)/partial metabolic response (PMR)/stable metabolic disease (SMD)/progressive metabolic disease (PMD) were 8/10/4/18 for EORTC criteria and 9/9/4/18 for PERCIST. Using RECIST1.1, those of CR/PR/SD/PD were 4/10/12/14. Although there was high concordance between PERCIST and EORTC (92.5% of patients; κ=0.924), that between PERCIST and RECIST1.1 was substantial (65.0%; κ=0.560) and that between EORTC and RECIST1.1 (65.0%; κ=0.574). After a median 23.2 months (range 7.2 to 51.8 months), 32 patients had documented progression and 24 patients died from NSCLC. According to both PET and CT, patients with no progression (CMR/PMR/SMD or CR/PR/SD) showed significantly longer PFS and OS than PMD or PD patients (EORTC: P0.0001 and P0.0001, respectively, PERCIST: P0.0001 and P=0.0001, respectively, RECIST1.1: P0.0001 and P0.0001, respectively). In a univariate analysis total MTV (P=0.042) on pre-ICI treatmentBoth